David McCall, MD
UT MD Anderson · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David McCall, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:01 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07551583 · Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLM.D. Anderson Cancer Center · recruiting · Hodgkin Lymphoma · principal investigator
- Ph2NCT06561074 · A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)M.D. Anderson Cancer Center · recruiting · T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma · principal investigator
- Ph1NCT06466395 · A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated LeukemiasM.D. Anderson Cancer Center · recruiting · Refractory Acute Leukemia, Relapsed Acute Leukemia, Undifferentiated Leukemia · principal investigator
- Ph1NCT06397027 · A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute LeukemiasM.D. Anderson Cancer Center · recruiting · Refractory Acute Leukemia, Pediatric Relapsed · principal investigator
- Ph2NCT05645718 · Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaM.D. Anderson Cancer Center · recruiting · Leukemia · principal investigator
- Ph2NCT05355051 · A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's LymphomaM.D. Anderson Cancer Center · recruiting · Hodgkin's Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.